drugset

drugset / Trial / NCT01015521

Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

NCT01015521 ↗

Phase 2 Withdrawn 50 enrolled Tigris Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.

Timeline

Start: 2010-04
Primary completion: 2012-12
Completion: —

Outcome

Outcome not reported

Stopped: “Study was not initiated as planned”

Publications

Saito R, Miki Y, Hata S, Ishida T, Suzuki T, Ohuchi N, Sasano H. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Res Treat. 2017 Feb;161(3):399-407. doi: 10.1007/s10549-016-4063-x. Epub 2016 Nov 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aminoflavone Prodrug	Unknown	—	—

Indications